Latest Cervarix Stories
Helps Protect Against Nine HPV types - Including Types that Cause About 90% of Cervical Cancer Cases KIRKLAND, QC, April 1, 2015 /CNW Telbec/ - Merck (NYSE: MRK), known as MSD outside
SGO, ASCCP leverage newly published end-of-study data to support option of HPV primary screening for women 25 and older INDIANAPOLIS, Jan.
Expansion Comes After Successful Phase II Trial for Cervical Dysplasia PLYMOUTH MEETING, Pa., Sept. 22, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc.
KIGALI, Rwanda, Aug. 27, 2014 /PRNewswire-USNewswire/ -- Seraphine Mukandutiye, 50, is a Rwandan woman with a beautiful and glowing smile.
LA JOLLA, Cali., Aug. 22, 2014 /PRNewswire/ -- Research presented at the 29(th) Annual International Papillomavirus Conference shows that a therapy being developed by Hera Therapeutics Inc.
A long-term follow-up study (HPV-023; NCT00518336) shows the sustained efficacy, immunogenicity and safety of GlaxoSmithKline's human papilloma virus (HPV) vaccine Cervarix. Women vaccinated with the HPV-16/18 AS04-adjuvanted vaccine were followed for more than nine years, and vaccine efficacy (VE) against incident infection was 100%.
Inovio Responds to False and Misleading Speculation Regarding Immunotherapy Study BLUE BELL, Pa., June 11, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc.
LONDON, June 10, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
Teenage girls who practice risky sex have higher rates of HPV and herpes than those in the general population according to a study reported on Healio.com on May 20, 2014 (1).
ST. PAUL, Minn., Feb.
- A serpent whose bite was fabled to produce intense thirst.